Safety and tolerability of T-SIGn vectors when administered using “flat” versus “low-high-high” (LHH) dosing regimens.

NG-641 - Akamis Bio

Opdivo (nivolumab) - Ono Pharma, BMS

enadenotucirev (ColoAd1) - Akamis Bio, BMS

Keytruda (pembrolizumab) - Merck (MSD)

NG-350A - Akamis Bio

Thomas Lillie; Lee S. Rosen; David Krige; Minesh Patel; Isabel Prieto González-Albo; Jo Carter; Behnaz Ravanfar; Vladimir Evilevitch; Aung Naing

Apr 28, 2022